載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.005
+US$0.1326 · +15.20%
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
一般交易時段
US$1.005
+US$0.1326 · +15.20%
盤中時間採用ET。市場資料可能有所延遲。
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
日內區間
目前US$1.005
52週區間
目前US$1.005
盤中時間採用ET。市場資料可能有所延遲。
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
日內區間
目前US$1.005
52週區間
目前US$1.005
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 銷貨成本 | — | — | — | 1266 USD |
| 毛利 | — | — | — | −1266 USD |
| 研究與開發 | 410.02萬 USD | 420.5萬 USD | 408.13萬 USD | 39.29萬 USD |
| 銷售、一般及管理費用 | 935.41萬 USD | 675.37萬 USD | 354.95萬 USD | 230.75萬 USD |
| 營業費用 | 1346.12萬 USD | 1096.06萬 USD | 763.28萬 USD | 270.04萬 USD |
| 利息收入 | 22.38萬 USD | 30.93萬 USD | 24.91萬 USD | — |
| 利息支出 | — | — | 1.71萬 USD | 10.71萬 USD |
| 折舊和攤銷 | 6874 USD | 1880 USD | 1980 USD | 1266 USD |
| 營業利益 | −1346.12萬 USD | −1096.06萬 USD | −763.28萬 USD | −270.16萬 USD |
| 淨利 | −1323.74萬 USD | −1065.14萬 USD | −835.71萬 USD | −671.43萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$32.00
上漲空間 3084.08%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年8月20日 | 1:15 | — | — |
已生效 2024年8月20日
1:15
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
